PAR2 pepducins as a novel treatment of idiopathic pulmonary fibrosis
Ended Project Grant Awarded Last action
- Award ID
- R42HL140701
- Recipient
-
Oasis Pharmaceuticals, LLC UEI F2ZWBFV5NZ86
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,716,843
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Lexington, MA 02420, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $740,572 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $750,502 | |
| Original award | $225,769 |
Quick answers
Who received award R42HL140701?
R42HL140701 was awarded to Oasis Pharmaceuticals, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on May 15, 2018.
How much is award R42HL140701 worth?
$1,716,843 has been obligated on R42HL140701.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award